Crispr valuation is no match for reality
A patient death overshadowed the first data from a human trial of the company’s allogeneic Car-T therapy CTX110.
Roche buys into Prothena... kind of
The Swiss group moves to start a further trial of prasinezumab, but this will not be phase III.
Aptinyx data reveal statistical trauma
An attempt to abrogate the placebo response does not seem to have gone as planned.
US cuts fees for Covid-19 tests
Slower labs are to be paid less for Covid-19 tests, but will the move actually speed things up?
Small Galapagos setback prompts a bigger loss of sentiment
A mid-stage clinical failure raises more doubts about Galapagos’s pipeline and the wisdom of Gilead’s $5bn deal last year.
